| 1.075 -0.095 (-8.12%) | 08-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.52  |
1-year : | 1.77 |
| Resists | First : | 1.3 |
Second : | 1.51 |
| Pivot price | 1.25 |
|||
| Supports | First : | 0.95 |
Second : | 0.79 |
| MAs | MA(5) : | 1.16 |
MA(20) : | 1.27 |
| MA(100) : | 1.27 |
MA(250) : | 2.57 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.7  |
D(3) : | 10.9 |
| RSI | RSI(14): 31.6 |
|||
| 52-week | High : | 7.01 | Low : | 0.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DRMA ] has closed below the lower bollinger band by 14.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.2 - 1.21 | 1.21 - 1.22 |
| Low: | 0.94 - 0.94 | 0.94 - 0.95 |
| Close: | 1.06 - 1.07 | 1.07 - 1.09 |
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Thu, 30 Jul 2026
Dermata Therapeutics, Inc. Revenue Breakdown – NASDAQ:DRMA - tradingview.com
Mon, 27 Jul 2026
Dermata Therapeutics Inc (DRMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Mon, 27 Jul 2026
DRMA|Dermata Therapeutics Inc|Price:1.197|Chg%:+0.017 - tradingkey.com
Thu, 25 Jun 2026
DRMA Forecast — Price Target — Prediction for 2027 - tradingview.com
Mon, 15 Jun 2026
Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch - timothysykes.com
Mon, 15 Jun 2026
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 24.8 (%) |
| Held by Institutions | 7.3 (%) |
| Shares Short | 65 (K) |
| Shares Short P.Month | 93 (K) |
| EPS | -4.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.7 % |
| Return on Equity (ttm) | -103.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.26 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|